Prilenia Neurotherapeutics
Treatments for Neurodegenerative and Neurodevelopmental Disorders
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
Prilenia Neurotherapeutics | 02/07/2022 | NeuroPharmacology | NeuroBioTechnology | Biotechnology & Biopharmaceutical | Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis) | Biochemical: pharmacological drugs (Developing drugs) | 01/01/2018 | "11-50" |
Prilenia Neurotherapeutics is a clinical-stage biotech company and the developer of pridopidine, a highly selective sigma-1 receptor (S1R) agonist with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.
Pridopidine has been shown to maintain functional capacity in early HD patients, as measured by total functional capacity (TFC). Furthermore, it was recently selected from an international competition of over 30 potential therapeutics for inclusion in the first ever ALS platform trial, led by the Healey Center for ALS at Massachusetts General Hospital. Pridopidine is currently in late-stage clinical development for HD and ALS. The global phase 3 clinical trial in HD is active and recruiting, while the platform trial in ALS is expected to commence in Q4 2020. In the face of compelling results these trials could potentially lead to the registration of pridopidine for these indications.